Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHaydale Plc Regulatory News (HAYD)

Share Price Information for Haydale Plc (HAYD)

Share Price is delayed by 15 minutes
Get Live Data
0.33    0.005 (1.54%)
Bid:
0.32
Ask:
0.34
Spread: 0.02 (6.25%)
Market Cap: £25.66m
HAYD Live PriceLast checked at - London Stock Exchange

Intraday Haydale Plc Share Chart

Haydale US placed into insolvency process

10 Feb 2025 07:00

RNS Number : 4271W
Haydale Graphene Industries PLC
10 February 2025
 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF THE MARKET ABUSE REGULATION (EU) 596 / 2014 WHICH FORMS PART OF UK LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("MAR").

 

Haydale Graphene Industries plc

('Haydale' or the 'Group')

Haydale US placed into insolvency process

 

Ammanford, 10 February 2025 - Haydale (AIM: HAYD), the advanced materials group, announces that, further to the Group's announcement of 23 December 2024 regarding the completion of the reconstituted Board's business review, the Board has lodged the necessary filings in court in the state of Georgia (the "Court") to place its wholly owned subsidiary, Haydale Ceramic Technologies LLC, ("HCT") into a corporate insolvency process under Chapter 11 subchapter V of the United States ("US") Bankruptcy Code, and a Court hearing is expected to be held over the next few days to consider the commencement of the process.

 

Under the protection of the Chapter 11 subchapter V process, the Group then intends to proceed to file a proposed plan with the Court to sell the assets of HCT through a court supervised process pursuant to section 363 of the US Bankruptcy Code (the "Plan") via a public auction. This is seen by management as the best means of realising maximum value for those assets and giving the greatest potential for cash to be returned to Haydale (which has an outstanding intercompany debtor balance within the US sub group of £12.8m to the Group (the "Intergroup Balance")) after all liabilities of HCT have been settled, albeit there can be no guarantee of any such outcome. The Group has received several expressions of interest from third party companies that are expected to participate in the process.

 

Chapter 11 subchapter V is a court-supervised process for small companies that provides protection from pre-existing creditors whilst the sales process is effected. During this process, HCT will remain in possession and control of its assets to allow the business and operations to continue uninterrupted. It is anticipated that HCT will remain in Chapter 11 for a period of up to 90 days; HCT has sufficient access to working capital to fund itself through this process.

 

HCT comprises the Group's Silicon Carbide and cutting tool manufacturing facility based in Greer, South Carolina, with sales offices serving the North American, European and East Asian markets. In the Group's results for the year to 30 June 2024 Haydale US generated revenues of £3.3m, making pre-tax losses of £0.8m, and had net liabilities of £4.7m at the same balance sheet date.

 

Over the last few years, the Group has strategically repositioned its US operations by expanding focus from silicon carbide (SiC) powder sales to the manufacture and distribution of advanced cutting tools. This transition aimed to enhance value by moving up the supply chain and capitalising on the growing demand in sectors such as aerospace and automotive. Despite these strategic initiatives, the expected growth in the Group's US operations has not materialised. It has become clear to the reconstituted Board that the previous management team's confidence in the US business' ability to convert the pipeline on a timely basis was overly optimistic and not reflective of the Group's operational preparedness or knowledge of market conditions. Despite efforts to improve the performance of the US business, the Board expects HCT to remain loss-making beyond FY25 and has concluded that divestment of the US operations is in the best interests of the Company and its shareholders. In arriving at this decision, the Directors considered other possible scenarios, though concluded that the time required, costs and intervening persistent cash drain on the Group would not be justified.

 

The chosen course of action will significantly reduce overhead costs and operational complexity, contributing to the Group's goal of achieving improved profitability and cash flow in FY25, in order to protect Haydale's core business. Substantial cost savings in FY25 will be realised through the elimination of ongoing operating losses and associated overheads in the US business.

 

The remaining Intergroup Balances and investment not already provided against by Haydale as at 30 June 2024 will be provided against in full in the interim accounts to 31 December 2024.

 

Following the above process, the sale of the Group's South Korean Subsidiary as announced on 23 December 2024, and the exit from the Thailand operations effected earlier in January 2025, Haydale will comprise the Group's UK based nanomaterials business that facilitates the integration of graphene and other nanomaterials into the next generation of industrial materials and commercial technologies, incorporating Haydale's rich base of c100 patents.

 

Further announcements will be made at the appropriate time.

For further information:

Haydale Graphene Industries plc

Simon Turek, Chief Executive Officer Tel: +44 (0) 1269 842946

Gareth Kaminski-Cook, Non-Executive Chair

Patrick Carter, CFO

www.haydale.com

Cavendish Capital Markets Limited (Nominated Adviser & Broker)

Julian Blunt / Edward Whiley / Trisyia Jamaludin, Corporate Finance Tel: +44 (0) 20 7220 0500

Andrew Burdis, ECM

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDUWSBRVVUURAR
Date   Source Headline
11th Jun 20267:00 amRNSContract Win
21st May 20267:05 amRNSProposed Commercial Relationship
8th Apr 20265:18 pmRNSDirector/PDMR Shareholding
7th Apr 20267:00 amRNSNew Contract Signed
26th Mar 20263:39 pmRNSResult of AGM
6th Mar 20261:31 pmRNSInvestor Presentation via Investor Meet Company
2nd Mar 20267:00 amRNSStrategic Digital Infrastructure Partnership
17th Feb 20267:00 amRNSFinal Results and Post-Period Trading Update
11th Feb 20267:00 amRNSNotice of Annual Results
30th Jan 20269:45 amRNSTotal Voting Rights
22nd Jan 20264:54 pmRNSHolding(s) in Company
22nd Jan 20267:00 amRNSHolding(s) in Company
21st Jan 202612:31 pmRNSHolding(s) in Company
15th Jan 20265:01 pmRNSHolding(s) in Company
15th Jan 20262:44 pmRNSChange of Name
12th Jan 20267:00 amRNSCompletion of Acquisition
9th Jan 20266:19 pmRNSDirector/PDMR Dealings
8th Jan 20261:59 pmRNSHolding(s) in Company
8th Jan 20261:55 pmRNSHolding(s) in Company
6th Jan 20262:45 pmRNSResult of General Meeting and Total Voting Rights
22nd Dec 20252:08 pmRNSHolding(s) in Company
22nd Dec 20252:08 pmRNSHolding(s) in Company
16th Dec 202512:45 pmRNSResult of Retail Offer
15th Dec 20259:14 amRNSResult of Accelerated Bookbuild
12th Dec 20257:05 amRNSRetail Offer
12th Dec 20257:00 amRNSProposed Fundraise and Acquisition
2nd Dec 20257:00 amRNSCommercial Update
30th Oct 202510:45 amRNSExpansion of Commercial Platform
23rd Oct 20257:00 amRNSContract Wins
11th Sep 20257:00 amRNSStrategic Collaboration and Trading Update
8th Aug 20257:00 amRNSGrant of Share Options and PDMR Dealings
11th Jul 20258:21 amRNSHolding(s) in Company
30th Jun 20253:14 pmRNSHolding(s) in Company
26th Jun 20252:00 pmRNSSubscriptions, Director Dealings & Issue of Equity
12th Jun 20252:12 pmRNSTrading Update
23rd Apr 20255:22 pmRNSDirectorate Change
17th Apr 202510:46 amRNSCorrection: Haydale US Sales Process Update
17th Apr 20257:00 amRNSHaydale US Sales Process Update
2nd Apr 20257:00 amRNSHaydale Achieves CE Certification
13th Mar 20252:15 pmRNSSubscription, Director Dealings and TVR
13th Mar 20257:00 amRNSInterim Results
7th Mar 202510:18 amRNSHaydale US sales process update
10th Feb 20257:00 amRNSHaydale US placed into insolvency process
30th Dec 20245:20 pmRNSReplacement: Result of AGM
30th Dec 202412:48 pmRNSResult of AGM
23rd Dec 20247:05 amRNSDisposal of Korean Subsidiary
23rd Dec 20247:00 amRNSBusiness Review and Appointment of CEO
6th Dec 20247:00 amRNSPosting of Annual Report and Notice of AGM
4th Dec 20249:44 amRNSHolding(s) in Company
3rd Dec 20245:38 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.